Publications by authors named "B Kassai"
Article Synopsis
- The PHAGEinLYON Clinic program was established in 2022 to enhance access to pharmaceutical-grade phage therapy in France.
- In 2022, 143 requests for phage therapy were made, and after review, 57 patients were confirmed as candidates, with 33 ultimately receiving treatment for various bacterial infections.
- The program led to a positive clinical outcome for 69% of treated patients, showcasing the potential effectiveness of phage therapy in managing complex infections.
Background And Purpose: Disabling dystonia despite optimal medical treatment is common in Wilson disease (WD). No controlled study has evaluated the effect of deep brain stimulation (DBS) on dystonia related to WD. This study was undertaken to evaluate the efficacy of DBS on dystonia related to WD.
View Article and Find Full Text PDFTiny pills, big impacts: A systematic review on the endocrine disrupting effects of paediatric pharmaceuticals.
Environ Toxicol Pharmacol
October 2024
Endocrine disrupting chemicals (EDCs) may impact children's health, with medicines as a possible exposure source. Objective: to assess the potential impact of substances in paediatric medications and essential oils on children as EDC. It is a systematic review of five databases including Medline following the PECOT approach.
View Article and Find Full Text PDFArticle Synopsis
- Endocrine disruptors (ED) are widespread pollutants linked to chronic diseases, particularly affecting vulnerable groups like infants and children, highlighting a need for better information for parents.
- A study conducted at Lyon Mother and Child Hospital surveyed 746 individuals, including 444 pediatric healthcare professionals and 302 parents, revealing that while most had heard of ED, only 10% of parents and 5% of professionals felt well-informed about them.
- The findings showed that professionals generally had better knowledge than parents (73% vs. 60%), but only a small percentage had engaged with scientific literature or training on EDs, indicating the necessity for specific educational initiatives.
Background And Objectives: Creatine transporter deficiency (CTD) is a rare X-linked genetic disorder characterized by intellectual disability (ID). We evaluated the clinical characteristics and trajectory of patients with CTD and the impact of the disease on caregivers to identify relevant endpoints for future therapeutic trials.
Methods: As part of a French National Research Program, patients with CTD were included based on (1) a pathogenic variant and (2) ID and/or autism spectrum disorder.